Evidence map›Paper›PMID 34296348›Full record

ArticleCurrent genetics2021

Homology length dictates the requirement for Rad51 and Rad52 in gene targeting in the Basidiomycota yeast Naganishia liquefaciens.

Maierdan Palihati, Hideo Tsubouchi, Bilge Argunhan, Rei Kajitani, Omirgul Bakenova, Yong-Woon Han, Yasuto Murayama, Takehiko Itoh, Hiroshi Iwasaki

Abstract read
PubMed Publisher
In one paragraph

Article in Current genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Maierdan PalihatiSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.ORCID http://orcid.org/0000-0002-9859-3873
Hideo TsubouchiSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan. htsubouchi@bio.titech.ac.jp.ORCID http://orcid.org/0000-0003-0814-8432
Bilge ArgunhanInstitute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.ORCID http://orcid.org/0000-0002-6023-7654
Rei KajitaniSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.ORCID http://orcid.org/0000-0002-5013-0052
Omirgul BakenovaSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Yong-Woon HanSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Yasuto MurayamaSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Takehiko ItohSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Hiroshi IwasakiSchool and Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan. hiwasaki@bio.titech.ac.jp.ORCID http://orcid.org/0000-0002-0153-6873
Tokyo Institute of Technology · JPNational Institute of Genetics · JP

Funding

Japan Society for the Promotion of Science 17K15061Japan Society for the Promotion of Science 18H02371Japan Society for the Promotion of Science 18H03985Japan Society for the Promotion of Science 20K15713
6 · The paper itself

Abstract

Here, we report the development of methodologies that enable genetic modification of a Basidiomycota yeast, Naganishia liquifaciens. The gene targeting method employs electroporation with PCR products flanked by an 80 bp sequence homologous to the target. The method, combined with a newly devised CRISPR-Cas9 system, routinely achieves 80% gene targeting efficiency. We further explored the genetic requirement for this homologous recombination (HR)-mediated gene targeting. The absence of Ku70, a major component of the non-homologous end joining (NHEJ) pathway of DNA double-strand break repair, almost completely eliminated inaccurate integration of the marker. Gene targeting with short homology (80 bp) was almost exclusively dependent on Rad52, an essential component of HR in the Ascomycota yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe. By contrast, the RecA homolog Rad51, which performs homology search and strand exchange in HR, plays a relatively minor role in gene targeting, regardless of the homology length (80 bp or 1 kb). The absence of both Rad51 and Rad52, however, completely eliminated gene targeting. Unlike Ascomycota yeasts, the absence of Rad52 in N. liquefaciens conferred only mild sensitivity to ionizing radiation. These traits associated with the absence of Rad52 are reminiscent of findings in mice.

Indexed as

Gene TargetingBasidiomycotaCRISPR-Cas SystemsFungal ProteinsGene EditingGenetic Complementation TestGenetic EngineeringGenetic LociHomologous RecombinationIntramolecular OxidoreductasesKu AutoantigenRad51 RecombinaseRad52 DNA Repair and Recombination ProteinTransformation, GeneticFungal ProteinsIntramolecular OxidoreductasesKu AutoantigenRad51 RecombinaseRad52 DNA Repair and Recombination ProteinBasidiomycotaCRISPR-Cas9DNA repairGene targetingHomologous recombinationNaganishia liquefaciens

Identifiers

PMID34296348
OpenAlexW3183189542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.